Comparison · NCT01413178-ebc7dcbf
Busulfan + Melphalan vs Melphalan: Progression-Free Survival (PFS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Busulfan + Melphalan vs Melphalan: Progression-Free Survival (PFS). Trial comparisons, record NCT01413178-ebc7dcbf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01413178-ebc7dcbf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.692 | 0.598 | 0.773 | wilson | |
| Risk in group 2 | 0.51 | 0.413 | 0.607 | wilson | |
| Risk difference, group 1 minus group 2 | 0.182 | 0.0471 | 0.309 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.36 | 1.08 | 1.71 | log | |
| Odds ratio, group 1 over group 2 | 2.16 | 1.22 | 3.84 | log | |
| Number needed to treat, for one more participant with the outcome on Busulfan + Melphalan than on Melphalan | 5.49 | 3.24 | 21.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Busulfan + Melphalan | Busulfan with a target daily area under the curve (AUC) of 5000 with Melphalan 70 mg/m2 followed by a stem cell transplant | 72 | 104 | OG000 |
| Group 2 | Melphalan | High-dose Melphalan 200 mg/m2/day followed by a stem cell transplant | 50 | 98 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Progression-Free Survival (PFS)
- Description
- Participants that are still alive and without Multiple Myeloma 3 years after Stem cell Transplantation.
- Time frame
- 3 years after transplant
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
- NCT number
- NCT01413178
- Phases
- PHASE3
- Conditions
- Myeloma
- Interventions
- Busulfan, Melphalan, Questionnaire, G-CSF, High Dose Melphalan, Stem cell transplant
- Lead sponsor
- M.D. Anderson Cancer Center
- Results first posted
- 2020-04-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01413178?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01413178-ebc7dcbf